akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLCakusherstvo-67Research ArticleREVIEW ARTICLEНАУЧНЫЙ ОБЗОРCLINICAL AND BIOCHEMICAL ASPECTS OF THE USE OF MAGNESIUM IN OBSTETRICS, GYNECOLOGY AND PERINATOLOGYКЛИНИЧЕСКИЕ И БИОХИМИЧЕСКИЕ АСПЕКТЫ ПРИМЕНЕНИЯ ПРЕПАРАТОВ МАГНИЯ В АКУШЕРСТВЕ, ГИНЕКОЛОГИИ И ПЕРИНАТОЛОГИИДадакК.DadakK.МакацарияА. Д.MakatsariyaA. D.gemostasis@mail.ruБлиновД. В.BlinovD. V.ЗимовинаУ. В.ZimovinaU. V.Департамент акушерства и гинекологии, Кафедра фундаментального и углубленного международного высшего образования, Венский медицинский университет (Австрия)АвстрияDepartment of Gynecology and Obstetrics, Department of basic and advanced international postgraduate education, Medical University of Vienna (Austria)AustriaГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава РФ, МоскваРоссияFirst Moscow State Medical Sechenov University of the Ministry of Health Russian FederationRussian FederationГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РФ, МоскваРоссияThe Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, MoscowRussian Federation201407062016826978Copyright © Dadak K., Makatsariya A.D., Blinov D.V., Zimovina U.V., 20162016Дадак К., Макацария А.Д., Блинов Д.В., Зимовина У.В.Dadak K., Makatsariya A.D., Blinov D.V., Zimovina U.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/67

Significant biochemical role of magnesium in the body is well-known, as well as good proven clinical efficacy of magnesium in obstetrics and gynecology. Magnesium preparations, in particular magnesium sulfate, are recommended as the treatment of choice for premature birth, pre-eclampsia and eclampsia. There is evidence and its neuroprotective effects on the fetus. Restricts the use of magnesium sulfate possibility of overdose with serious side effects. Reduce the risk of overdose can be minimized using standard protocols, independent double-check, monitoring the patient’scondition. Magnesium sulfate therapy, as a means of emergency, cannot compensate for a deficiency of magnesium, which is associated with the development of obstetric pathologies such as threatened miscarriage, premature birth, placental insufficiency, preeclampsia, thrombophilia, premenstrual syndrome (PMS), the appointment of combined oral contraceptives (COCs) and hormone replacement therapy (HRT), climacteric syndrome. Justified use of organic salts of magnesium orally – along with better bioavailability they do not lead to serious side effects in overdose. Using organicmagnesium salts to control magnesium deficiency and related symptoms is also shown at the ICP, and the appointment of COCs HRT during menopause. The use of magnesium citrate is the most preferred because citrate anion causes high bioavailability of magnesium, it is also required in the Krebs cycle and recycled into carbon dioxide and water. Thismakes it an ideal transporter of magnesium into cells.

Значимая биохимическая роль магния в организме хорошо известна, также доказана клиническая эффективность препаратов магния в акушерстве и гинекологии. Препараты магния, в частности сульфат магния, рекомендованы как препараты выбора при преждевременных родах, преэклампсии и эклампсии. Есть данные и о его нейропротекторном воздействии на плод. Ограничивает применение сульфата магния возможность передозировки с развитием серьезных побочных эффектов. Свести риск передозировки к минимуму можно, используя стандартные протоколы, независимую двойную проверку, мониторинг состояния пациенты. Магнезиальная терапия, являясь средством экстренной помощи, не может восполнить дефицит магния, который связан с развитием акушерскогинекологической патологии, такой как угроза прерывания беременности, преждевременные роды, плацентарная недостаточность, преэклампсия, тромбофилии, предменструальный синдром (ПМС), назначение комбинированных оральных контрацептивов (КОК) и заместительной гормональной терапии (ЗГТ), климактерический синдром. Оправданно использовать органические соли магния перорально - наряду с лучшей биодоступностью, они не приводят к серьезным побочным эффектам при передозировке. Использование органических солей магния для контроля магниевого дефицита и связанных с ним симптомов показано также при ПМС, назначении КОК и ЗГТ при климаксе. Применение цитрата магния является наиболее предпочтительным, так как цитрат-анион обуславливает высокую биоусвояемость магния, он также необходим в цикле Кребса и утилизируется в углекислый газ и воду. Это делает цитрат идеальным переносчиком магния в клетки.

МАГНИЙПРЕЭКЛАМПСИЯЭКЛАМПСИЯПМСКОМБИНИРОВАННЫЕ ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫКОКЗГТЦИТРАТ МАГНИЯmagnesiumpreeclampsiaeclampsiaPMScombined oral contraceptivesCOCHRTmagnesium citrateReferencesБлинов Д.В. Общность ряда нейробиологических процессов при расстройствах деятельности ЦНС. Эпилепсия и пароксизмальные состояния. 2011; 2: 28-33.Blinov D.V. Epilepsiya i paroksizmal’nye sostoyaniya. 2011; 2: 28-33.Блинов Д.В. Объективные методы определения тяжести и прогноза перинатального гипоксически-ишемического поражения ЦНС. Акушерство, гинекология и репродукция. 2011 (2): 5-12.Blinov D.V. Akusherstvo, ginekologiya i reproduktsiya. 2011 (2): 5-12.Громова О.А., Лиманова О.А., Торшин И.Ю. Систематический анализ фундаментальных и клинических исследований указывает на необходимость совместного использования эстроген-содержащих препаратов с препаратами пиридоксина и магния. Акушерство, гинекология и репродукция. 2013; 7 (3): 35-50.Gromova O.A., Limanova O.A., Torshin I.Yu. Akusherstvo, ginekologiya i reproduktsiya. 2013; 7 (3): 35-50.Громова О.А. Дефицит магния как проблема современного питания у детей и подростков. Педиатрическая Фармакология. 2014; 1: 20-30.Gromova O.A. Pediatricheskaya Farmakologiya. 2014; 1: 20-30.Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Джобава Э.М. Распространенность дефицита магния у беременных женщин, наблюдающихся в условиях амбулаторной практики. Вопросы гинекологии акушерства и перинатологии. 2012; 11: 25-34.Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Dzhobava E.M. Voprosy ginekologii akusherstva i perinatologii. 2012; 11: 25-34.Роль дефицита магния в акушерстве и гинекологии (позиция экспертов). Коллектив авторов. Акушерство и Гинекология. 2014; 1.Role of magnesium deficiency in obstetrics and gynecology (position paper). The authors. [Rol’ defitsita magniya v akusherstve i ginekologii (pozitsiya ekspertov). Kollektiv avtorov]. Akusherstvo i Ginekologiya. 2014; 1.Справочные данные Минздравсоцразвития РФ, НЦ АГиП имени академика Кулакова. М. 2008.Reference data. Ministry of Health; SCOGP [Spravochnye dannye Minzdravsotsrazvitiya RF, NTs AGiP imeni akademika Kulakova]. Moscow. 2008.Стрижаков А.Н. и др. Биологическая роль магния в акушерстве и гинекологии: научные данные и клиническое исследование. Вопросы гинекологии, акушерства и перинатологии. 2009; 8 (3): 5-18.Strizhakov A.N. i dr. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (3): 5-18.Amighi J., Sabeti S. et al. Low Serum Magnesium Predicts Neurological Events in Patients with Advanced Atherosclerosis. Stroke. 2004: 35:22Amighi J., Sabeti S. et al. Low Serum Magnesium Predicts Neurological Events in Patients with Advanced Atherosclerosis. Stroke. 2004: 35:22Almonte R.A., Heath D.L., Whitehall J., Russell M.J., Patole S., Vink R. Gestational magnesium deficiency is deleterious to fetal outcome. Biol. Neonate. 1999 Jul; 76 (1): 26-32.Almonte R.A., Heath D.L., Whitehall J., Russell M.J., Patole S., Vink R. Gestational magnesium deficiency is deleterious to fetal outcome. Biol. Neonate. 1999 Jul; 76 (1): 26-32.Crowther C.A., Hiller J.E., Doyle L.W. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews. 2002; 4. Art. No.: CD001060.Crowther C.A., Hiller J.E., Doyle L.W. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews. 2002; 4. Art. No.: CD001060.Crowther C.A., Hiller J.E., Doyle L.W., Haslam R.R.; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003; 290 (20): 2669-2676.Crowther C.A., Hiller J.E., Doyle L.W., Haslam R.R.; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003; 290 (20): 2669-2676.Doyle L.W., Crowther C.A., Middleton P., Marret S., Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews. 2009; 1. Art. No.: CD004661.Doyle L.W., Crowther C.A., Middleton P., Marret S., Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews. 2009; 1. Art. No.: CD004661.Duley L., Gülmezoglu A.M., Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2010; 9: CD002960.Duley L., Gülmezoglu A.M., Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2010; 9: CD002960.Ebel H., Gunther T. Magnesium metabolism: a review. J. Clin. Chem. & Clin. Biochem. 1998; 18: 257-70.Ebel H., Gunther T. Magnesium metabolism: a review. J. Clin. Chem. & Clin. Biochem. 1998; 18: 257-70.Feldeisen S.E., Tucker K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab. 2007; 32 (1): 46-60.Feldeisen S.E., Tucker K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab. 2007; 32 (1): 46-60.Higdon J. An Evidence-Based Approach to Vitamins and minerals. New York-Stuttgart, 2005.Higdon J. An Evidence-Based Approach to Vitamins and minerals. New York-Stuttgart, 2005.Jackson R.A., Gibson K.A., Wu Y.W. et al. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet. And Gynecol. 2004; 104 (2): 551-563.Jackson R.A., Gibson K.A., Wu Y.W. et al. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet. And Gynecol. 2004; 104 (2): 551-563.Leitich H., Brumbauer M., Kaider A. et al. Cervical length and dilation of the internal as detected by vaginal ultrasonography as markers for preterm delivery: a systematic review. Am. J. Obstet. Gynecol. 1999; 181: 1465-1472.Leitich H., Brumbauer M., Kaider A. et al. Cervical length and dilation of the internal as detected by vaginal ultrasonography as markers for preterm delivery: a systematic review. Am. J. Obstet. Gynecol. 1999; 181: 1465-1472.Medication Errors in Labor and Delivery: Reducing Maternal and Fetal Harm. Pa Patient Saf. Advis. 2009; 16 (6; Suppl. 1): 1-6.Medication Errors in Labor and Delivery: Reducing Maternal and Fetal Harm. Pa Patient Saf. Advis. 2009; 16 (6; Suppl. 1): 1-6.Mercer B.M., Goldenberg R.L., Moawad A.H. et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am. J. Obstet. Gynecol. 1999; 181: 1216-1221.Mercer B.M., Goldenberg R.L., Moawad A.H. et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am. J. Obstet. Gynecol. 1999; 181: 1216-1221.Mercer B.M., Merlino A.A. Magnesium sulfate for preterm labor and preterm birth. Obstet. Gynecol. 2009; 114 (3): 650-668.Mercer B.M., Merlino A.A. Magnesium sulfate for preterm labor and preterm birth. Obstet. Gynecol. 2009; 114 (3): 650-668.Ogoma Y., Kobayashi H., Fujii T., Kondo Y., Hachimori A., Shimizu T., Hatano M. Binding study of metal ions to S100 protein: 43Ca, 25Mg, 67Zn and 39K n.m.r. Int. J. Biol. Macromol. 1992; 14 (5): 279-286.Ogoma Y., Kobayashi H., Fujii T., Kondo Y., Hachimori A., Shimizu T., Hatano M. Binding study of metal ions to S100 protein: 43Ca, 25Mg, 67Zn and 39K n.m.r. Int. J. Biol. Macromol. 1992; 14 (5): 279-286.Qina J., Chaia G., Brewerb J.M., Lovelacea L.L., Lebiodaa L. Structures of asymmetric complexes of human neuron specific enolase with resolved substrate and product and an analogous complex with two inhibitors indicate subunits interaction and inhibitors cooperativity. J. Inorg. Biochem. 2012 June; 111: 187-194.Qina J., Chaia G., Brewerb J.M., Lovelacea L.L., Lebiodaa L. Structures of asymmetric complexes of human neuron specific enolase with resolved substrate and product and an analogous complex with two inhibitors indicate subunits interaction and inhibitors cooperativity. J. Inorg. Biochem. 2012 June; 111: 187-194.Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am. J. Ther. 2001; 8 (5): 345-357.Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am. J. Ther. 2001; 8 (5): 345-357.Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16 000 individuals. Magnes Res. 2001; 14 (4): 283-90.28, 30.Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16 000 individuals. Magnes Res. 2001; 14 (4): 283-90.28, 30.Rouse D.J., Hirtz D.G., Thom E., Varner M.W. et al. Eunice Kennedy Shriver NICHD Maternal- Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359 (9): 895-905.Rouse D.J., Hirtz D.G., Thom E., Varner M.W. et al. Eunice Kennedy Shriver NICHD Maternal- Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359 (9): 895-905.Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 2001 Dec; 14 (4): 283-90.Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 2001 Dec; 14 (4): 283-90.Schreier B., Hocker B. Engineering the enolase magnesium II binding site: implications for its evolution. Biochemistry. 2010; 49: 7582-7589.Schreier B., Hocker B. Engineering the enolase magnesium II binding site: implications for its evolution. Biochemistry. 2010; 49: 7582-7589.Spätling L., Disch G., Classen H.G. Magnesium in pregnant women and the newborn. Magnes Res. 1989 Dec; 2 (4): 271-80.Spätling L., Disch G., Classen H.G. Magnesium in pregnant women and the newborn. Magnes Res. 1989 Dec; 2 (4): 271-80.Sriboonlue P., Jaipakdee S., Jirakulsomchok D., Mairiang E., Tosukhowong P., Prasongwatana V., Savok S. Changes in erythrocyte contents of potassium, sodium and magnesium and Na, K-pump activity after the administration of potassium and magnesium salts. J. Med. Assoc. Thai. 2004; 87 (12): 1506-1512.Sriboonlue P., Jaipakdee S., Jirakulsomchok D., Mairiang E., Tosukhowong P., Prasongwatana V., Savok S. Changes in erythrocyte contents of potassium, sodium and magnesium and Na, K-pump activity after the administration of potassium and magnesium salts. J. Med. Assoc. Thai. 2004; 87 (12): 1506-1512.WHO – recommended definitions, terminology and format for statistical tables related to perinatal period and use of a new certificate for cause of perinatal deaths. Acta Obstet. Gynecol. Scand. 1977; 56 (3): 247–253.WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. World Health Organization, Dept. of Reproductive Health and Research, Dept. of Maternal, Newborn, Child and Adolescent Health, Dept. of Nutrition for Health and Development. 2011. 38 p.WHO – recommended definitions, terminology and format for statistical tables related to perinatal period and use of a new certificate for cause of perinatal deaths. Acta Obstet. Gynecol. Scand. 1977; 56 (3): 247–253.WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. World Health Organization, Dept. of Reproductive Health and Research, Dept. of Maternal, Newborn, Child and Adolescent Health, Dept. of Nutrition for Health and Development. 2011. 38 p.Wynn A., Wynn M. Magnesium and other nutrient deficiencies as possible causes of hypertension and low birthweight. Nutr. Health. 1988; 6 (2): 69-88.Wynn A., Wynn M. Magnesium and other nutrient deficiencies as possible causes of hypertension and low birthweight. Nutr. Health. 1988; 6 (2): 69-88.

The authors declare that there are no conflicts of interest present.